anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Subjects in the treatment group will be administered MOVANTIK™ (naloxegol) 25 mg tablet or placebo once daily beginning 2 hours after the completion of their surgery until their discharge from the hospital (variable timing). Subjects with renal impairments (creatine clearance rate of less than 60 mL/min) will receive a 12.5 mg dose tablet of naloxegol in place of the 25 mg dose as advised by FDA guidelines. For patients who are unable to swallow the tablet whole, the tablet can be crushed and given orally or administered via nasogastric tube.
PURPOSE:To obtain the subject excellent cosmetic effective in eliminating the rough feeling of the skin caused by application, promoting the moistness of the skin and giving durable make-up and absolutely free from allergic reaction, by using kojic acid as an active component. CONSTITUTION:The objective cosmetic contains kojic acid as an active component. Kojic acid is a known substance produced by culturing a microbial strain belonging to genus Aspergillus, Penicillium, Escherichia, Acetobacter or Gluconobacter, active to suppress melanogenesis and having extremely low toxicity. The amount of kojic acid to be compounded to the make-up cosmetic is 0.01-5.0wt.%, preferably 0.1-2.0wt.% based on the whole make-up cosmetic. The cosmetic is compounded with powder and used in the form of powder, pressed powder, etc., such as foundation, etc. The powder to be compounded to the cosmetic is e.g. talc, kaolin, nylon powder, etc.
The invention provides a method of delivering a therapeutic agent to the adventitia of a vessel using a catheter-based microsyringe. A therapeutic agent is formed into microparticles, which are dispersed throughout an appropriate liquid carrier to form a therapeutic mixture. A catheter is provided that includes a microsyringe operably attached to an actuator. The microsyringe includes a hollow needle in fluid communication with a therapeutic agent delivery conduit. The catheter is introduced into a target area of a vessel. The actuator is operated to thrust the needle into a wall of the vessel. The therapeutic mixture is supplied to the therapeutic agent delivery conduit and delivered through the conduit to the needle and thereby into the adventitia of the vessel. The actuator is again operated to withdraw the needle from the wall of the vessel and to enclose it within the actuator. The catheter is then removed from the vessel.
Prolonged labor, especially during the second stage of active expulsive effort (the pushing phase), is associated with increased risk of maternal complications (e.g. tissue trauma, postpartum hemorrhage, intra-amniotic infection). Developing an effective method to assist and maximize maternal expulsion effort should be of great value in reducing the number of complications, also including cesarean section or instrumental deliveries. Past studies published in the dental literature have shown that specially designed oral appliances that support the dental occlusion may increase the isometric strength of different muscle groups. Increased strength of the neck muscles could improve efficiency of the Valsalva maneuver in increasing intra-uterine pressure, and thus decreasing the duration of phase II of labor. Nulliparous women with uncomplicated singleton pregnancy will be randomly assigned to either the study group (Dental appliance) or the no dental appliance group. Duration of labor will be measured for both phase I and phase II. Rates for cesarean section and instrument deliveries and other complications will be charted as well as Apgar scores .
A dental impression material comprises a gel-forming agent such as ammonium carboxymethyl cellulose, a salt containing a metallic ion which reacts in solution with the agent to form an elastic gel having a specific pH value, and an indicator which changes colour as the gel point is reached.  The salts may be hydrated calcium sulphate, lead monosilicate, lead disilicate, basic lead sulphate, basic lead carbonate, and salts of zinc and strontium.  Retarders such as sodium carbonate, trisodium phosphate and polyphosphate, sodium meta-, ortho- and pyrophosphate, and alkali metal salts of substituted acids of ethylene diamine, and fillers such as powdered talc, clay, diatomaceous earth, calcium carbonate and silica, may also be added. The indicator chosen depends on the mix used and may change colour at a pH from 6 to 10. Specifications 518,596 and 641,654, [both in Group V], are referred to.ALSO:A dental impression material comprises a gelforming agent, a salt containing a metallic ion which reacts in solution with the agent to form an elastic gel having a specific pH value, and an indicator which changes colour as the gel point is reached.  The gel-forming agent may be sodium, potassium, or ammonium alginate; alkali metal pectins or pectates, or sodium, potassium, or ammonium carboxy methyl cellulose.  The metal salts may be hydrated calcium sulphate, lead monosilicate, lead disilicate, basic lead sulphate, basic lead carbonate and salts of zinc and strontium. Retarders such as sodium carbonate, trisodium phosphate and polyphosphate, sodium meta-, ortho-, and pyrophosphate, and alkali metal salts of substituted acids of ethylene diamine; and fillers such as powdered talc; clay, diatomacious earth, calcium carbonate and silica may also be added.  The indicator chosen depends on the mix used and may change colour at a pH of from 6 to 10.  In specific examples, rosolic acid is used as indicator in a mix consisting of diatomaceous earth, potassium alginate, tetrasodium pyrophosphate, sodium fluosilicate and either calcium sulphate hemihydrate or lead silicate or both.  Specifications 518,596 and 641,654 are referred to.
In children with receiving palliative care will be randomly divided into two groups: audiobook group and musical-moving toy. Interventions will be applied for 2 days, 1 times a day (2 sessions). No intervention will be applied to both groups besides audiobook or musical-moving toy intervention. The children will be assessed before, during and after. Pain, fear and anxiety due to tracheostomy care procedure will be evaluated using the Wong Baker Facial Pain Scale, Child Anxiety Scale-Stateness and Children's Fear Scale . In addition, the heart rate, respiration, blood pressure and SPO2 values of the children will be measured with the help of a bedside monitor.
The invention discloses a radiotherapy protective ointment composed of pure traditional Chinese medicines. The radiotherapy protective ointment is prepared from the following raw materials in parts by weight: 20-22 parts of aloe, 12-14 parts of pseudo-ginseng, 5-7 parts of olive oil, 10-12 parts of dragon's blood, 18-20 parts of gromwell, 8-10 parts of elephant hide powder, 3-5 parts of fresh water pearl, 3-5 parts of multiflower knoweed stem, 2-4 parts of borneol, 10-12 parts of radix astragali, 5-7 parts of giant knotweed, 3-5 parts of radix rehmanniae and 1-3 parts of sesame oil. The product can be used before or after the radiotherapy, and has unexpected effects. By using the superior composition, the product improves the blood circulation of the whole body and partial body, and promotes absorption of the wound surface inflammation from the aspect of enhancing the immunity and regenerative capacity of organisms. By using multiple traditional Chinese medicinal materials as the monarch and minister components, the product has the effects of promoting tissue regeneration, enhancing immunity, promoting blood circulation and absorbing inflammatory wound surfaces. The clinical application over the years proves that the ointment has excellent curative effects on radioactive skin protection and injury therapy.
PURPOSE:To provide a new compound having excellent cyclic GMP phosphodiesterase-inhibiting action and useful as an agent for the prevention and treatment of various diseases caused by the enzyme, e.g. a hypotensive diuretic agent or a bronchodilator. CONSTITUTION:The compound of formula (R is n-pentyl, 3-methyl-n-pentyl, n-hexyl, 5-methyl-n-hexyl, n-heptyl or 5-methyl-n-heptyl). The compound can be produced by culturing a bacterial strain belonging to the genus Streptomyces and capable of producing WS63967 substance [Streptomyces griseochromogenes (FERM BP-3659)] in a nutrient medium containing carbon and nitrogen sources under aerobic condition, extracting with a solvent and purifying the extract. The compound of formula has the following properties. Appearance, dark green plate crystal; solubility, easily soluble in DMF and DMSO, slightly soluble in acetone, chloroform and methanol, insoluble in water; color reaction, positive to cerium sulfate reaction and iodine vapor reaction and negative to Molisch's reaction.
BACKGROUND/AIMS: : Functional dyspepsia (FD) has long been regarded as a syndrome because its pathophysiology is multifactorial. However, recent reports have provided evidence that changes in the duodenal ecosystem may be the key. This study aimed to identify several gastrointestinal factors and biomarkers associated with FD, specifically changes in the duodenal ecosystem that may be key to understanding its pathophysiology.
METHODS: : In this case-control study, 28 participants (12 with FD and 16 healthy control individuals) were assessed for dietary nutrients, gastrointestinal symptom severity, immunological status of the duodenal mucosa, and microbiome composition from oral, duodenal, and fecal samples. Integrated data were analyzed using immunohistochemistry, real-time polymerase chain reaction, 16S rRNA sequencing, and network analysis.
RESULTS: : Duodenal mucosal inflammation and impaired expression of tight junction proteins were confirmed in patients with FD. The relative abundance of duodenal Streptococcus (p=0.014) and reductions in stool Butyricicoccus (p=0.047) were confirmed. These changes in the gut microbiota were both correlated with symptom severity. Changes in dietary micronutrients, such as higher intake of valine, were associated with improved intestinal barrier function and microbiota.
CONCLUSIONS: : This study emphasizes the relationships among dietary nutrition, oral and gut microbiota, symptoms of FD, impaired function of the duodenal barrier, and inflammation. Assessing low-grade inflammation or increased permeability in the duodenal mucosa, along with changes in the abundance of stool Butyricicoccus, is anticipated to serve as effective biomarkers for enhancing the objectivity of FD diagnosis and monitoring.
The first 6 month period of the study will employ a ketamine-based protocol for prehospital agitation. There will be a tiered dosing protocol based on degree of agitation.
Healthy adults aged 65-75 will participate in three study days where they are randomly assigned to receive either nicotine patch, oral mecamylamine, placebo and perform a working memory task during the fMRI. BOLD signal is the outcome measure.
A composition for oral ingestion by humans comprising a mixture of glucomannan and cannabidiol and one or more carrier substances. Preferably, the composition is a solid composition, most preferably a chewy pastille (gummy). The oral composition comprising the dietary fibre glucomannan in combination with cannabidiol acts as an appetite suppressant and may be used in assisting weight loss. Also disclosed is a chewable pastille comprising a chewable base comprising a gelling agent and a sugar and/or a sugar alcohol; glucomannan; and a cannabis extract containing cannabidiol. Preferably, the chewable base comprises the sugar alcohol sorbitol and/or the gelling agent agar. Other gelling agents may include pectin or gelatin. The cannabis extract containing cannabidiol may consist of a cannabis extract oil e.g. in sunflower oil. Other substances may also be included in the pastille compositions including flavouring agents, non-sugar sweeteners, colouring agents, vegetable oils, natural waxes and anticaking agents. The oral composition may be administered with or before the ingestion of food.
An activity monitoring system measures the effectiveness of pain management using using data from motion or activity sensors attached to the patient's body to compute measures of exertion level of a patient. Increased levels of exertion are an indication of successful pain management. The patient's walking gait smoothness and walking gait stability are also graded as indicators of pain management effectiveness. The motion or activity sensors may be part of a temporary stimulation system used during percutaneous trials, part of a permanent implanted system, or an independent sensor package carried on the patient's body. The particular location and axes of the motion or activity sensors may be chosen based on the location of the pain being treated. The effectiveness of a particular pain management stimulation parameter set is based on the statistics accumulated over a period of time, for example one hour.
Participants will perform targetted movement exercises by interacting with the RehabTouch pucks, as described and monitored on a computer. Participants will be asked to exercise at least 3 hours per week for 3 consecutive weeks.
The invention refers to a fungicidal composition comprising two or three active components in which as an active element I is used metalaxyl containing more than 70 mass. % of R-enantiomer. In quality of the component II may be used: mancozeb (IIA), chlorothalonil (IIB), copper inorganic compounds (IIC), folpet (IID), fluazinam (IIE), zimoxanyl (IIF), utilized independently or as a third component of mixture with one of above mentioned component. In addition, it is claimed a process for control and prevention of plants Oomycetes infection. The technical result consists in improvement of the obtained composition fungicidal activity. Claims: 20 <IMAGE>
Pilates exercises and Yoga are two effective treatments for correcting RSP. In Pilates each exercise is conducted in more than one times usually three to five hence exposing the body to different and new muscular and kinesthetic challenges. On the other hand Yoga is a process in which the joints and muscles operate together in a systematic and automatic manner where each pose is sustained for a period of time. Several literatures support the belief that Pilates exercises and Yoga are effective treatments for RSP correction, as well as improving sleep quality, heart rate and SpO2 First, The participants will be divided into two groups, for Pilates exercises and Yoga. Honor wristbands will be distributed and Exercises will be demonstrated to each group. Explanation of using Honor band will be given. Measurements will be taken before the intervention including cervical ROM. shoulder ROM at baseline, 2nd week and 4th week. while heart rate, SpO2 immediately after the session. Sleep quality prior the intervention, 2nd and 4th week. Patients will do the exercises 3 times per week for 4 consecutive weeks.
Participants will be provided an 8-week home exercise program that they will complete. The participants will also be provided all of the equipment. An investigator will contact them weekly to ensure compliance and send You Tube videos with new Phases.
Procedure for the stereoselective obtaining of derivatives of imidazoliloximas, whose formas trans and cis have, respectively, the formulas (I) and (II), where to is an aromatic and im is the group 1-h-imidazolilo, which can be substituted. The procedure of obtaining, both for the trans form and for the cis, part of a 2-halogen-etona of formula (III), in which it has the meaning above and ha1 is a halogeno atom. For the obtaining of the form cis, the starting ethanone is reactioned, first with imidazole and the product obtained, in hot and in alcoholic solution, with hydroxylamine or with a derivative of hydroxylamine. For the obtaining of the trans form, the starting ethanone is reacted, in alcoholic solution and above the ambient temperature, with hydroxylamine or with a derivative thereof, and to the product obtained with imidazole or with a derivative of imidazole, in an appropriate and cold solvent. These compounds present antimictic activity. *formula* (Machine-translation by Google Translate, not legally binding)
The present invention includes a package for a medicament for treating infectious disease. The package comprises a first vessel and a second vessel. The first vessel contains a solid mixture of a biguanide antimicrobial agent and a polyol. The polyol has a melting point above room temperature. The ratio of biguanide antimicrobial agent to polyol is a maximum of about 1:5 and a minimum of about 1:1000. The solid mixture comprises less than 10 wt. % water based upon its total weight. The second vessel comprises an aqueous diluent. The present invention includes methods of manufacturing the package and methods of treating infection.
We determined natural antibodies (n-Abs) to the regulators of the main systems of biochemical homeostasis: β-endorphin, serotonin, dopamine, histamine, orphanin, angiotensin, GABA, glutamate, bradykinin, vasopressin, thrombin, and α-2-macroglobulin in individuals with phantom pain syndrome (PPS), resulting from amputation after injury. It was established that each patient has an individual immunoprofile, but for all of them there was a significant increase in the level of antibodies to serotonin, histamine, and angiotensin, which reflect the chronicity of the pain syndrome and do not depend on the self-assessment of the severity of PPS. Determination of the role of regulators of biochemical homeostasis in the development of phantom pain showed that, at high, moderate, and weak severity of PPS, the biogenic amine and angiotensinergic systems are activated. A decrease in PPS intensity normalizes deviations in all immunological parameters. The levels of n-Abs for the pain (β-endorphin) and analgesic (orphanin) systems are significant only at low PPS. Monitoring the individual profile of n-Abs to endogenous regulators allows us to obtain an objective picture of the pain status of the patient's body.
Rapid increases in bone mass occur during calcium absorption and bone calcium deposition during puberty, and these increases can enhance peak bone mass and ultimately decrease the lifetime risk of osteoporosis. However, dietary, hormonal, and genetic factors likely affect increased bone mass. This study will examine if adding NDO to a pubertal diet allows more absorption of calcium by the body, producing stronger bones. The study will also assess how the hormones produced by the body during puberty affect bone growth and whether genetic factors affect calcium absorption or bone growth.

This study will last 2 years. At study entry, baseline pubertal hormone levels and bone mass will be assessed. Both a dual-energy X-ray absorptiometry (DEXA) scan and a calcium stable kinetic study measuring calcium absorption will be performed. Participants will then be randomly assigned to receive calcium fortified food with or without added NDO for 1 year. Calcium absorption will be measured again at 2 months. After the first year, calcium kinetic, hormonal, and DEXA studies will be performed and compared to baseline results. A final DEXA scan will be performed at the end of 2 years.
The investigators analyze the intraocular pressure changes on patients who have been using Agomelatine for their primary depressive disorder. For the treatment of depression, patients will have been started routinely Agomelatine tablet of 25 mg orally. The investigators measure the eye pressure for one months in those patients receiving standard depression treatment.
Participants will receive 28 telephone sessions over a 12 month period by interventionists trained in behavior change skills and motivational interviewing techniques. Participants will be asked to monitor food intake and physical activity using the LoseIt website/app and weight daily using a Body Trace e-scale. Participants will receive feedback on self-monitoring through e-mail. Dietary goals will be based on weight and participants' weight-loss progress. Participants will be encouraged to replace 2 meals and a snack with meal replacements (provided). Participants will be asked to gradually increase their moderate to vigorous exercise to 225-250 minutes per week. The Toolbox includes additional treatment options (e.g., food scales, exercise videos, cookbooks) for those who wish to take advantage of them. There will be several challenges that will provide a specific goal (e.g. increase self-monitoring), with a small award for completion.
There is a range of genomic aberrations from aneuploidy down to single base pair deletions or inserts. Present technology uses microscopic cytogenetics for detection of large rearrangements (greater than 2 Mb) and molecular techniques for small rearrangements (less than 2 Mb). There is a gap in practical diagnostic technology in that microscopic cytogenetics has poor sensitivity for aberrations less than 5 Mb and the molecular techniques are cumbersome for clinical use in the megabase range. In many cases it is possible to determine that an aberration is present by microscopic cytogenetics but cannot be characterized. We propose to use Spectral Karyotyping (SKY) and supplementary FISH and molecular techniques to characterize these aberrations. Subjects will be seen in OP9 for a clinical genetics evaluation and phlebotomy for SKY. Confirmation of SKY results will be performed by standard FISH, genomic content mapping, and other standard techniques.
A system and method for identification of key driver responsible for bringing changes in a microbial population is provided. The method involves construction of microbial association networks with each microbial taxa as nodes and their associations as edges and subsequent identification of crucial ‘driver’ nodes involved in the studied disease progression. While comparing a particular node between two networks, this method takes individual nodes and their associations into account as well as the identity of their interacting partners. A taxon in the diseased state with an altered set of associations while still being increasingly important for the whole network necessarily holds a key significance in microbial interplay. Using this rationale, this methodology computes a score to quantify this change for each node and calculates its statistical significance. Subsequently, ‘driver’ nodes are identified using the score coupled with other network parameters and a critical score for the ‘driver’ nodes is calculated to quantify its importance.
The present invention provides mammalian protein tyrosine phosphatases, human PTP-BAS type 4, human PTP-BAS type 5a and mouse PTP-BAS type 5b, each of which is a Fas-associated protein (FAP), nucleic acid molecules encoding a PTP-BAS type 4 or a PTP-BAS type 5 and antibodies specific for a PTP-BAS type 4 or for a PTP-BAS type 5. The invention also provides methods for identifying FAP's, which can associate with Fas and can modulate apoptosis. The invention also provides screening assays for identifying an agent that can effectively alter the association of a FAP with Fas and, therefore, can increase or decrease the level of apoptosis in a cell. The invention further provides methods of modulating apoptosis in a cell by introducing into the cell a nucleic acid molecule encoding a PTP-BAS or fragment of a PTP-BAS or an antisense nucleotide sequence, which is complementary to a portion of a nucleic acid molecule encoding a PTP-BAS. The invention also provides a method of using a reagent that can specifically bind to a FAP to diagnose a pathology that is characterized by an increased or decreased level of apoptosis in a cell. The invention also provides methods of modulating apoptosis in a cell by contacting the cell with an agent that effectively alters the association of a FAP and Fas in a cell or alters the activity of a FAP in a cell.
The sevoflurane concentration via the ventilator and the oxygenator fresh gas supply was titrated to maintain a target BIS value between 40 and 60 (BIS-Monitor, Covidien, Boulder, Colorado, USA). However, the concentration of sevoflurane in the oxygenator fresh gas supply was not reduced below 0.3%.